The Potential Role of the Endogenous Opioid System in the Antidepressant Effect of Ketamine
Botros B. Shenoda
Research in Neurology An International Journal February 3, 2014 DOI: 10.5171/2014.733320 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Topics | Esketamine Ketamine |
| Citations | 4 |
| Key findings | Argues that the endogenous opioid system may play a role in ketamine's antidepressant effect, noting that the opioid system is dysregulated in depression and that ketamine interacts with it directly or indirectly via endogenous opioid release. Contends that ketamine's modulation of the opioid system warrants in-depth investigation for potential antidepressant effects. |
Abstract
The noncompetitive NMDA receptor blocker ketamine provides significant improvement to patients suffering from depression but its mechanistic pathways are not fully understood.The endogenous opioid system is known to be dysregulated in patients with depression.Ketamine is known to interact with the opioid system either directly or indirectly through the release of endogenous opioids.In this review, I am discussing the potential role that might be played by the endogenous opioid system in conferring the antidepressant effect of ketamine and emphasizing that the modulation of the opioid system by ketamine warrants in-depth investigation for potential antidepressant effect.
Comparable studies
Other narrative reviews on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms | 2018 | Review | |
| Mechanisms of Ketamine Action as an Antidepressant | 2018 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) | 2013 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement |
Citations in the library
Cites 18
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder The Journal of Clinical Psychiatry July 13, 2010
- Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial The International Journal of Neuropsychopharmacology March 17, 2009
- Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression The International Journal of Neuropsychopharmacology October 8, 2013
and 13 more in the library